Peter Buggisch

13.2k citations
233 papers · 10.2k · 6 hit papers · h-index 38

Impact in

  • Hepatology top 0.05%
    • Hepatitis C virus research
    • Liver Diseases and Immunity
    • Hepatocellular Carcinoma Treatment and Prognosis
    • Hepatitis Viruses Studies and Epidemiology
  • Epidemiology top 0.2%
    • Hepatitis B Virus Studies
    • Liver Disease Diagnosis and Treatment

Papers in

    • Hepatitis C virus research 169
    • Liver Diseases and Immunity 23
    • Liver Disease and Transplantation 12
    • Liver Disease Diagnosis and Treatment 68
    • Hepatitis B Virus Studies 60

Peter Buggisch

220 papers receiving 9.7k citations

Peter Buggisch's Hit Papers

A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis 2024 · 166 citations
1660+10+21Years since publication4008001.2k

Peers

Peter Buggisch
Comparison fields: 5 of 129
  • Hepatology 6.7k
  • Epidemiology 5.6k
  • Infectious Diseases 829
  • Oncology 805
  • Immunology 496
Replace William Sievert with:
William Sievert Australia
Robert Reindollar United States
Eiji Tanaka Japan
Maria Grazia Rumi Italy
Jean‐Pierre Zarski France
Reem H. Ghalib United States
Lennox J. Jeffers United States
Elizabeth Jenny Heathcote Canada
Antonina Smedile Italy
Giovanna Fattovich Italy
Peter Buggisch relative to William Sievert Australia William Sievert's profile →
Citations per field
00.5×1.5×2×2.3×
William Sievert · 1×
Citations per year

Countries citing papers authored by Peter Buggisch

Since Specialization
Citations

This map shows the geographic impact of Peter Buggisch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Buggisch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Buggisch more than expected).

Fields of papers citing papers by Peter Buggisch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Buggisch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Buggisch. The network helps show where Peter Buggisch may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Buggisch, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Buggisch Line = papers co-authored together Peter Buggisch links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 233 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Hit paper breakdown →
20141457
2
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B
Hit paper breakdown →
2008968
3
Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
Hit paper breakdown →
1994535
4
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Hit paper breakdown →
2012485
5
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B 1 1The Adefovir Dipivoxil International 461 Study Group includes the following: N. Afdhal (Beth Israel Deaconess Medical Center, Boston, MA); P. Angus (Austin and Repatriation Medical Centre, Melbourne, Australia); Y. Benhamou (Hopital La Pitie Salpetriere, Paris, France); M. Bourliere (Hopital Saint Joseph, Marseille, France); P. Buggisch (Universitaetsklinikum Eppendorf, Department of Medicine, Hamburg, Germany); P. Couzigou (Hopital Haut Leveque, Pessac, France); P. Ducrotte and G. Riachi (Hopital Charles Nicolle, Rouen, France); E. Jenny Heathcote (Toronto Western Hospital, Toronto, Ontario, Canada); H. W. Hann (Jefferson Medical College, Philadelphia, PA); I. Jacobson (New York Presbyterian Hospital, New York, NY); K. Kowdley (University of Washington Hepatology Center, Seattle, WA); P. Marcellin (Hopital Beaujon, Clichy, France); P. Martin (Cedars-Sinai Medical Center, Los Angeles, CA); J. M. Metreau (Centre Hospitalier Universitaire Henri Mondor, Creteil, France); M. G. Peters (University of California, San Francisco, San Francisco, CA); R. Rubin (Piedmont Hospital, Atlanta, GA); S. Sacks (Viridae Clinical Sciences, Inc., Vancouver, Canada); H. Thomas (St. Mary’s Hospital, London, England); C. Trepo (Hopital Hôtel Dieu, Lyon, France); D. Vetter (Hopital Civil, Strasbourg, France); C. L. Brosgart, R. Ebrahimi, J. Fry, C. Gibbs, K. Kleber, J. Rooney, M. Sullivan, P. Vig, C. Westland, M. Wulfsohn, and S. Xiong (Gilead Sciences, Inc., Foster City, CA); D. F. Gray (GlaxoSmithKline, Greenford, Middlesex, England); R. Schilling and V. Ferry (Parexel International, Waltham, MA); and D. Hunt (Covance Laboratories, Princeton, NJ).
2003467
6
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
Hit paper breakdown →
2017449
7 1998433
8 2010399
9 2006394
10 2006378
11 2009286
12 1993212
13 2006174
14 2017166
15
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
Hit paper breakdown →
2024166
16 2008154
17 2017133
18 2019126
19 2011116
20 2011107

About Peter Buggisch

Peter Buggisch is a scholar working on Hepatology, Epidemiology, Rheumatology, Infectious Diseases and Genetics, having authored 233 papers that have together received 10.2k indexed citations. Recurring topics across this work include Hepatitis C virus research (169 papers), Liver Disease Diagnosis and Treatment (68 papers), Hepatitis B Virus Studies (60 papers), Liver Diseases and Immunity (23 papers), Systemic Lupus Erythematosus Research (22 papers), HIV/AIDS drug development and treatment (18 papers), Liver Disease and Transplantation (12 papers) and Chronic Lymphocytic Leukemia Research (9 papers). The work is most often cited by research in Hepatology (6.7k citations), Epidemiology (5.6k citations), Infectious Diseases (829 citations), Oncology (805 citations) and Immunology (496 citations). Peter Buggisch has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Thomas Berg, Stefan Zeuzem, Christoph Sarrazin, Heiner H. Wedemeyer, Wolff Schmiegel, G. Riethmüller, Jens Witte, H. Pichlmaier, Rudolph Raab and K. Höffken. Their work appears in journals such as Journal of Hepatology, Hepatology, Liver International, Gastroenterology and Journal of Viral Hepatitis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact